Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation
Endothelial glycocalyx (EG) derangement has been associated with cardiovascular disease (CVD). Studies on EG integrity among people living with HIV (PLWH), are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received emtricitabine/tenofovir alafenamide, combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat). We assessed EG at baseline, 24 (±4) and 48 (±4) weeks, by measuring the perfused boundary region (PBR, inversely proportional to EG thickness), in sublingual microvessels. In total, 66 consecutive PLWH (60 (90.9%) males) with a median age (interquartile range, IQR) of 37 (12) years, were enrolled. In total, 40(60.6%) received INSTI-based regimens. The mean (standard deviation) PBR decreased significantly from 2.17 (0.29) μm at baseline to 2.04 (0.26) μm (p = 0.019), and then to 1.93 (0.3) μm (p < 0.0001) at 24 (±4) and 48 (±4) weeks, respectively. PBR did not differ among treatment groups. PLWH on INSTIs had a significant PBR reduction at 48 (±4) weeks. Smokers and PLWH with low levels of viremia experienced the greatest PBR reduction. This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Viruses - 15(2023), 7 vom: 05. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fragkou, Paraskevi C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 14.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v15071505 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360150616 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360150616 | ||
| 003 | DE-627 | ||
| 005 | 20240314234500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v15071505 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM360150616 | ||
| 035 | |a (NLM)37515191 | ||
| 035 | |a (PII)1505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fragkou, Paraskevi C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Endothelial glycocalyx (EG) derangement has been associated with cardiovascular disease (CVD). Studies on EG integrity among people living with HIV (PLWH), are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received emtricitabine/tenofovir alafenamide, combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat). We assessed EG at baseline, 24 (±4) and 48 (±4) weeks, by measuring the perfused boundary region (PBR, inversely proportional to EG thickness), in sublingual microvessels. In total, 66 consecutive PLWH (60 (90.9%) males) with a median age (interquartile range, IQR) of 37 (12) years, were enrolled. In total, 40(60.6%) received INSTI-based regimens. The mean (standard deviation) PBR decreased significantly from 2.17 (0.29) μm at baseline to 2.04 (0.26) μm (p = 0.019), and then to 1.93 (0.3) μm (p < 0.0001) at 24 (±4) and 48 (±4) weeks, respectively. PBR did not differ among treatment groups. PLWH on INSTIs had a significant PBR reduction at 48 (±4) weeks. Smokers and PLWH with low levels of viremia experienced the greatest PBR reduction. This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a antiretroviral treatment | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a endothelial glycocalyx | |
| 650 | 4 | |a integrase inhibitor | |
| 650 | 4 | |a permeable boundary region | |
| 650 | 4 | |a protease inhibitor | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Ikonomidis, Ignatios |e verfasserin |4 aut | |
| 700 | 1 | |a Benas, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Kavatha, Dimitra |e verfasserin |4 aut | |
| 700 | 1 | |a Moschopoulos, Charalampos D |e verfasserin |4 aut | |
| 700 | 1 | |a Protopapas, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Kostelli, Gavriella |e verfasserin |4 aut | |
| 700 | 1 | |a Thymis, John |e verfasserin |4 aut | |
| 700 | 1 | |a Mpirmpa, Dionysia |e verfasserin |4 aut | |
| 700 | 1 | |a Galani, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Tsakona, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Oikonomopoulou, Chrysanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Theocharous, George |e verfasserin |4 aut | |
| 700 | 1 | |a Gorgoulis, Vassilis G |e verfasserin |4 aut | |
| 700 | 1 | |a Gallos, Parisis |e verfasserin |4 aut | |
| 700 | 1 | |a Tsiodras, Sotirios |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniadou, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Triantafyllidi, Helen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 15(2023), 7 vom: 05. Juli |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:7 |g day:05 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v15071505 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 7 |b 05 |c 07 | ||